United States · 
Who invested in POINT Biomedical?
POINT Biomedical's investors include SR One, De Novo Ventures, Invesco Perpetual, Invesco Private Capital and CHL Medical Partners, and 1 more on record.
2008
$4.3MSeries G$25MSeries EUnited States · Series E startup
Who invested in POINT Biomedical
Funding summaryUpdated 26 Oct 2026
$29Mraised across 2 rounds since 2007, from 2 sources
$4.3MSeries G$25MSeries E
- Latest round
- Series E, $25MJan 2008
- Step-upi
- 5.8×
- Investors
- 6
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Series G, $4.3M Jul 2007
- Biggest round
- $25M Series E · Jan 2008
- Between rounds
- 6 months from the last two
The rounds
- Jan 2008Series E$25M6 new
From a historical funding record
- Jul 2007
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
De Novo VenturesGrowth equity1round
Invesco Private CapitalVC firm1round
CHL Medical PartnersVC firm1round
Missing a round, or an investor who was in one? Tell us.
Quick answers about POINT Biomedical
How much has POINT Biomedical raised?
POINT Biomedical has raised $29M across 2 rounds since 2007.
When did POINT Biomedical last raise?
POINT Biomedical's most recent round was a Series E of $25M in Jan 2008.
What was POINT Biomedical's biggest round?
Its most recent round, $25M in Jan 2008, is also its largest on record.
Who backed POINT Biomedical first?
POINT Biomedical's first round on record, in Jan 2008, was backed by SR One, De Novo Ventures and Invesco Perpetual and 3 others.
What stage is POINT Biomedical at?
POINT Biomedical's latest named round is a Series E, in Jan 2008.
Where is POINT Biomedical based?
POINT Biomedical is based in the United States.
Companies like POINT Biomedical
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.